ReShape Lifesciences signs exclusive license for Obalon balloon in South Asia

Vyome Holdings, Inc

Exclusive license to Biorad Medysis for Obalon balloon in India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka, Maldives.
$200,000 upfront plus 4% royalty on gross sales.
Biorad to become exclusive worldwide manufacturer under future supply agreement.
Territory covers ~20-25% of world population (~1.6-2 billion people).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vyome Holdings, Inc entered into License Agreement with Biorad Medysis Pvt. Ltd. valued at $200,000 in upfront payments (effective 2023-09-19).

Action: entry
Agreement: license
Counterparty: Biorad Medysis Pvt. Ltd.
Value: $200,000 in upfront payments
Effective: 2023-09-19

Exact text from the filing

On September 19, 2023, ReShape Lifesciences Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with Biorad Medysis Pvt. Ltd. (“Biorad”), pursuant to which the Company granted an exclusive license to Biorad to manufacture, commercialize and distribute the Company’s Obalon® Gastric Balloon System in the territory of India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka, and the Maldives.

View on SEC.gov

Browse all material agreements →

Vyome Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-103175

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.